专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008111092A1 CRYSTALLINE TEMOZOLOMIDE MONOHYDRATE AND PROCESS FOR PREPARATION THEREOF 审中-公开
标题翻译：结晶聚苯乙烯单硬脂酸酯及其制备方法
公开(公告)号：WO2008111092A1
公开(公告)日：2008-09-18
申请号：PCT/IN2008/000134
申请日：2008-03-10
申请人： DABUR PHARMA LIMITED , PANDA, Bijan , MAIKAP, Golak, Chandra , AGARWAL, Shiv, Kumar , SINGH, Manoj, Kumar , JAGGI, Manu
发明人： PANDA, Bijan , MAIKAP, Golak, Chandra , AGARWAL, Shiv, Kumar , SINGH, Manoj, Kumar , JAGGI, Manu
IPC分类号： C07D487/04
CPC分类号： C07D487/04
摘要： A crystalline Temozolomide Monohydrate. A process for preparing the same comprising: i) dissolving Temozolomide, having a purity of 50-70% in acetone at a temperature of about 50-55°C; ii) optionally adding activated carbon to the solution of step i); iii) filtering the activated carbon from the mixture of step ii); iv) evaporating the filtrate of step iii) to obtain a solid substance; v) dissolving the solid substance obtained in step iv) in a mixture of acetone and water in the ratio of 3:1 v/v at a temperature from about 50°C to reflux temperature; vi) optionally adding activated carbon to the solution of step v); vii) cooling the mixture of step vi) to ambient temperature; viii) filtering the activated carbon from the mixture of step vii); ix) cooling the filtrate of step viii) to a temperature of 0-5 °C and collecting the crystals and drying the filtrate of step viii) to give the crystalline Temozolomide Monohydrate.
摘要翻译：结晶替莫唑胺一水合物。一种制备该方法的方法，包括：i）在约50-55℃的温度下将纯度为50-70％的替莫唑胺溶于丙酮; ii）任选地将活性炭加入到步骤i）的溶液中; iii）从步骤ii）的混合物过滤活性炭; iv）蒸发步骤iii）的滤液以获得固体物质; v）将步骤iv）中获得的固体物质在约50℃至回流温度下以3:1v / v的比例溶解在丙酮和水的混合物中; vi）任选地将活性炭加入到步骤v）的溶液中; vii）将步骤vi）的混合物冷却至环境温度; viii）从步骤vii）的混合物过滤活性炭; ix）将步骤viii）的滤液冷却至0-5℃的温度，并收集晶体并干燥步骤viii）的滤液，得到结晶的替莫唑胺一水合物。

2. 发明申请

WO2006085334A3 NOVEL BETULINIC ACID DERIVATIVES A-RING-CONDENSED TO A HETEROCYCLIC GROUP 审中-公开
公开(公告)号：WO2006085334A3
公开(公告)日：2006-08-17
申请号：PCT/IN2005/000445
申请日：2005-12-29
申请人： DABUR PHARMA LIMITED , MUKHERJEE, Rama , SRIVASTAVA, Sanjay, Kumar , SIDDIQUI, Mohammad, Jamshed, Ahmed , JAGGI, Manu , SINGH, Anu, T. , VARDHAN, Anand , SINGH, Manoj, Kumar , RAJENDRAN, Praveen , JAJOO, Hemant, Kumar , BURMAN, Anand, C. , KUMAR, Vivek , RANI, Nidhi , AGARWAL, Shiv, Kumar
发明人： MUKHERJEE, Rama , SRIVASTAVA, Sanjay, Kumar , SIDDIQUI, Mohammad, Jamshed, Ahmed , JAGGI, Manu , SINGH, Anu, T. , VARDHAN, Anand , SINGH, Manoj, Kumar , RAJENDRAN, Praveen , JAJOO, Hemant, Kumar , BURMAN, Anand, C. , KUMAR, Vivek , RANI, Nidhi , AGARWAL, Shiv, Kumar
IPC分类号： C07J71/00 , A61K31/58 , A61P35/00
摘要： The invention relates to novel betulinic acid derivatives of formula (I), wherein R is C (=CH 2 ) CH 3 or CH(CH 3 ) 2 ; R 2 together with the adjacent carbonyl group forms a carboxylic acid, carboxylic acid ester or amide or substituted amide; R 3 or R 4 are hydrogen or aryl with the proviso that both are not independently hydrogen or alkyl or R 3 and R 4 are combined together to form an aryl ring optionally substituted with a group X, wherein X is selected from halogen, alkyl, cyano, nitro, alkoxy, amino or substituted amine; Y is N or O; and R 1 is zero when Y is O, and R 1 is hydrogen, alkyl or aryl alkyl when Y is N, useful for inhibition of tumor cancer cells. Formula (I)

3. 发明申请

WO2007074476A1 A BIOCOMPATIBLE, NON-BIODEGRADABLE, NON-TOXIC POLYMER USEFUL FOR NANOPARTICLE PHARMACEUTICAL COMPOSITIONS 审中-公开
标题翻译：一种可生物降解的，非生物降解的非毒性聚合物，用于纳米脂肪药物组合物
公开(公告)号：WO2007074476A1
公开(公告)日：2007-07-05
申请号：PCT/IN2006/000504
申请日：2006-12-26
申请人： DABUR PHARMA LIMITED , BURMAN, Anand, C. , MUKHERJEE, Rama , KHATTAR, Dhiraj , MULLICK, Sanjoy , JAGGI, Manu , SINGH, Manoj, Kumar , KUMAR, Mukesh , PRUSTHY, Deepak , GUPTA, Pawan, Kumar , PRAVEEN, Rajendran , SINGH, Shobhit
发明人： BURMAN, Anand, C. , MUKHERJEE, Rama , KHATTAR, Dhiraj , MULLICK, Sanjoy , JAGGI, Manu , SINGH, Manoj, Kumar , KUMAR, Mukesh , PRUSTHY, Deepak , GUPTA, Pawan, Kumar , PRAVEEN, Rajendran , SINGH, Shobhit
IPC分类号： C08F220/00
CPC分类号： A61K47/32 , C08F220/56 , C08F222/12 , C08F222/385 , C08F226/10
摘要： The invention relates to a biocompatible, non-biodegradable, and non-toxic polymer of formula (I), comprising of three monomeric units, selected from 1-Vinylpyrrolidone (VP), N-Isopropylacrylamide (NIPAM), and ester of Maleic anhydride and Polyethylene glycol (MPEG), cross-linked with a bi-functional vinyl derivative, of high purity and substantially free of respective toxic monomeric contaminants, and a process for preparation thereof. The invention further relates to nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds comprising the polymer of the invention, which are safe, less-toxic and convenient for bedside adminstration to patients in need thereof. Furthermore, the invention relates to a highly selective method for preparation of nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds.
摘要翻译：本发明涉及式（I）的生物相容性，不可生物降解的和无毒的聚合物，其包含三种选自1-乙烯基吡咯烷酮（VP），N-异丙基丙烯酰胺（NIPAM）和马来酸酐的单体单元和与双官能乙烯基衍生物交联的聚乙二醇（MPEG），其纯度高，基本上不含有毒的单体污染物及其制备方法。本发明还涉及难溶于水的药物或包含本发明的聚合物的化合物的纳米颗粒药物组合物，其对于有需要的患者的床边给药是安全的，毒性较小的和方便的。此外，本发明涉及用于制备难溶于水的药物或化合物的纳米颗粒药物组合物的高选择性方法。

4. 发明申请

WO2008114274A1 PROLIPOSOMAL AND LIPOSOMAL COMPOSITIONS 审中-公开
标题翻译：脂肪组织和脂肪组成
公开(公告)号：WO2008114274A1
公开(公告)日：2008-09-25
申请号：PCT/IN2008/000003
申请日：2008-01-04
申请人： DABUR PHARMA LIMITED , KHATTAR, Dhiraj , KUMAR, Mukesh , GARG, Minakshi , MUKHERJEE, Rama , BURMAN, Anand, C. , JAGGI, Manu , SINGH, Anu, T. , AWASTHI, Anshumali
发明人： KHATTAR, Dhiraj , KUMAR, Mukesh , GARG, Minakshi , MUKHERJEE, Rama , BURMAN, Anand, C. , JAGGI, Manu , SINGH, Anu, T. , AWASTHI, Anshumali
IPC分类号： A61K9/127 , A61K31/337
CPC分类号： A61K31/337 , A61K9/0019 , A61K9/1271 , A61K9/1277
摘要： Concentrates or proliposomal compositions of poorly water-soluble drugs and compounds, comprising of one or more membrane forming lipids, a membrane stabilizing agent, in a suitable vehicle, and optionally containing a Polyethylene Glycol (PEG)-coupled phospholipid or a mixture thereof and further, optionally containing pharmaceutically acceptable excipients such as antioxidants, buffering agents, acidifying agents etc. are provided, which have superior long term stability. The concentrates of proliposomal compositions instantly form liposomes of the said poorly water-soluble drugs and compounds on rapid injection to a diluting fluid, the liposomal composition so obtained, characterized by a physical stability more than 24 hours, ≥ 95% drug encapsulation and having a particle size diameter of less than 100 nm. The liposomal compositions so obtained can further be directly administered to patients in need of treatment of the poorly water-soluble drugs and compounds.
摘要翻译：水溶性差的药物和化合物的浓缩物或前体组合物，包含一种或多种形成膜的脂质，膜稳定剂，在合适的载体中，并且任选地含有聚乙二醇（PEG） - 偶联的磷脂或其混合物，任选地含有药学上可接受的赋形剂如抗氧化剂，缓冲剂，酸化剂等，其具有优异的长期稳定性。促乳素体组合物的浓缩物立即形成所述不良水溶性药物和化合物的脂质体，其快速注射至稀释液体，所得脂质体组合物的特征在于物理稳定性超过24小时，= 95％药物包封并具有粒度直径小于100nm。如此获得的脂质体组合物可以进一步直接施用于需要治疗不良水溶性药物和化合物的患者。

5. 发明申请

WO2009019721A2 NOVEL QUERCETIN DERIVATIVES AS ANTI-CANCER AGENTS FIELD OF THE INVENTION 审中-公开
标题翻译：作为抗癌剂的新型喹诺酮衍生物发明领域
公开(公告)号：WO2009019721A2
公开(公告)日：2009-02-12
申请号：PCT/IN2008/000496
申请日：2008-08-08
申请人： DABUR PHARMA LIMITED , JOSHI, Narendra Shriram , AGGARWAL, Pawan , HIRPARA, Vitthalbhai Ketan , JAGGI, Manu , SINGH, Anu T. , AWASTHI, Anshumali , VERMA, Ritu
发明人： JOSHI, Narendra Shriram , AGGARWAL, Pawan , HIRPARA, Vitthalbhai Ketan , JAGGI, Manu , SINGH, Anu T. , AWASTHI, Anshumali , VERMA, Ritu
CPC分类号： C07D311/30
摘要： The present invention provides novel Quercetin derivatives of formula (I) and pharmaceutically acceptable salts, hydrates, and solvates thereof, Formula (I): wherein R 1 is hydrogen, benzyl or substituted benzyl; R 2 is hydrogen, benzyl or substituted benzyl, linear or branched (C 1 -C 6 ) alkyl, substituted alkyl, aryl, substituted aryl, heterqcyele,and (Substituted heterocycle, useful for treatment of various disorders including cancer, multi-drug resistant cancers, viral infections etc. The invention also provides a process for the preparation of compounds of formula (I) and pharmaceutical compositions comprising the same.
摘要翻译：本发明提供式（I）的新型槲皮素衍生物及其药学上可接受的盐，水合物和溶剂合物，式（I）：其中R 1是氢，苄基或取代的苄基; R 2是氢，苄基或取代的苄基，直链或支链（C 1 -C 6）烷基，取代的烷基，芳基，取代的芳基，异胞核和（取代的杂环，可用于治疗各种疾病，包括癌症，多药耐药性癌症，病毒感染等。本发明还提供了制备式（I）化合物的方法和包含其的药物组合物。

6. 发明申请

WO2017003430A1 MOLECULAR AND HERBAL COMBINATIONS WITH METHOTREXATE FOR TREATING DISEASES AND INFLAMMATORY AILMENTS 审中-公开
标题翻译：用于治疗疾病和炎症性物质的甲基异黄酮的分子和草药组合
公开(公告)号：WO2017003430A1
公开(公告)日：2017-01-05
申请号：PCT/US2015/038341
申请日：2015-06-29
申请人： SIRBA LTD. , JAGGI, Manu , SINGH, Anu , SHRAIBOM, Nadav , STEINBERG, Eran
发明人： JAGGI, Manu , SINGH, Anu , SHRAIBOM, Nadav , STEINBERG, Eran
IPC分类号： A61K36/00
CPC分类号： A61K36/73 , A61K31/475 , A61K31/519 , A61K31/555 , A61K31/655 , A61K36/185 , A61K36/355 , A61K36/65 , A61K36/708 , A61K36/804 , A61K36/815 , A61K2300/00
摘要： A treatment regimen for psoriasis, eczema or other skin ailment, inflammation, autoimmune disease, leukemia, melanoma or other cancer includes administering to a patient a methotrexate regimen along with periodic doses of an herbal combination including Sheng Di Huang, Da Huang or Jin Yin Hua or combinations thereof.
摘要翻译：用于银屑病，湿疹或其它皮肤疾病，炎症，自身免疫性疾病，白血病，黑素瘤或其他癌症的治疗方案包括向患者施用甲氨蝶呤方案以及定期剂量的包括黄芪黄，大黄或金银华的草药组合或其组合。

7. 发明申请

WO2003004469A1 ANTICANCER ACTIVITY OF IMINO ACID CONJUGATES OF METHYLGLYOXAL 审中-公开
标题翻译：氨基甲酸的氨基酸结合物的反应活性
公开(公告)号：WO2003004469A1
公开(公告)日：2003-01-16
申请号：PCT/US2002/020753
申请日：2002-07-01
申请人： DABUR RESEARCH FOUNDATION , CORD, Janet, I. , BURMAN, Anand, C. , MUKHERJEE, Rama , JAGGI, Manu , SINGH, Anu, T. , KAPOOR, Kamal, K. , PRASAD, Sudhanand , RAY, Manju Indian Institute of Cultivation of Science
发明人： BURMAN, Anand, C. , MUKHERJEE, Rama , JAGGI, Manu , SINGH, Anu, T. , KAPOOR, Kamal, K. , PRASAD, Sudhanand , RAY, Manju Indian Institute of Cultivation of Science
IPC分类号： C07D207/28
CPC分类号： C07D207/28
摘要： The invention relates to the use of imino acid conjugates of methylglyoxal (I) for the inhibition and/or treatment of cancer. The invention relates more specifically to the use imino acid conjugates of methylglyoxal (I) for inhibition and/or treatment of cancer of the Colon, Prostate, Larynx, Kidney, Pancreas, Lung,Breast, Intestine, Oral Cavity, Ovary, Gliobastoma, and Leukemia. The invention also relates to compositions and methods of inhibiting cancer using imino acid conjugates of methylglyoxal (I).
摘要翻译：本发明涉及甲基乙二醛（I）的亚氨基酸缀合物用于抑制和/或治疗癌症的用途。本发明更具体地涉及使用甲基乙二醛（I）的亚氨基酸偶联物用于抑制和/或治疗结肠，前列腺，喉，肾，胰腺，肺，乳腺，肠，口腔，卵巢，胶质母细胞瘤和白血病。本发明还涉及使用甲基乙二醛（I）的亚氨基酸缀合物抑制癌症的组合物和方法。

8. 发明申请

WO2017172648A1 HERBAL NANOFORMULATIONS FOR TREATING PSORIASIS AND OTHER SKIN CONDITIONS 审中-公开
标题翻译：治疗皮肤瘙痒和其他皮肤病的草药纳米形貌
公开(公告)号：WO2017172648A1
公开(公告)日：2017-10-05
申请号：PCT/US2017/024378
申请日：2017-03-27
申请人： SIRBAL LTD. , SHRAIBOM, Nadav , STEINBERG, Eran , JAGGI, Manu , SINGH, Anu, T. , VERMA, Ritu , MADAAN, Alka
发明人： SHRAIBOM, Nadav , STEINBERG, Eran , JAGGI, Manu , SINGH, Anu, T. , VERMA, Ritu , MADAAN, Alka
IPC分类号： A61K36/355 , A61K36/708 , A61K36/804
摘要： A medicinal composition includes an active herbal component that is prepared by cooking a combination of Sheng Di Huang, Da Huang and Jin Yin Hua and has an average particulate size between 100-300nm. Example formulations include topical gels, tablets and capsules.
摘要翻译：药物组合物包括通过蒸煮生地黄，大黄和金银花的组合制备的具有100-300nm平均粒度的活性草药成分。实例制剂包括局部凝胶，片剂和胶囊剂。

9. 发明申请

WO2017091791A1 IDENTIFICATION OF BIOMARKERS IN SERUM SAMPLES COLLECTED FROM CLINICAL TRIALS BY MULTIPLEX TECHNOLOGY 审中-公开
标题翻译：多重技术从临床试验中收集的血清样品中生物标志物的鉴定
公开(公告)号：WO2017091791A1
公开(公告)日：2017-06-01
申请号：PCT/US2016/063706
申请日：2016-11-23
申请人： SIRBAL LTD. , SHRAIBOM, Nadav , SINGH, Anu, T. , JAGGI, Manu , STEINBERG, Eran , VERMA, Ritu , MADAAN, Alka
发明人： SHRAIBOM, Nadav , SINGH, Anu, T. , JAGGI, Manu , STEINBERG, Eran , VERMA, Ritu , MADAAN, Alka
IPC分类号： A61K8/97 , A61K36/00 , A61K36/355 , A61K36/708 , A61K36/804 , A61K38/19
CPC分类号： A61K36/708 , A61K36/355 , A61K36/804 , A61K38/19 , A61K45/06 , A61K2300/00
摘要： The present invention provides methods, compositions, and kits for the treatment and/or diagnosis of psoriasis. The invention includes a method for diagnosing psoriasis, comprising measuring a level or combination of levels of one or more of: IL-5, IL-6, IL-7, IL-10, IL-13, IL-33, FGF-B, GMCSF, VEGF, IL-33, MCP-1, or IP-10, or combinations thereof, in a sample from a patient; comparing said measured level or combination of levels; and correlating said level or combination of levels with a manifestation of psoriasis within said patient. A medicinal composition comprising an herbal combination of Da Huang, Sheng Di Huang, and Jin Yin Hua for the treatment of psoriasis in a patient. A kit for diagnosing and/or prognosing psoriasis in a patient.
摘要翻译：本发明提供用于治疗和/或诊断银屑病的方法，组合物和试剂盒。本发明包括用于诊断牛皮癣的方法，包括测量IL-5，IL-6，IL-7，IL-10，IL-13，IL-33，FGF-B中的一种或多种的水平或组合水平，GMCSF，VEGF，IL-33，MCP-1或IP-10或其组合在来自患者的样品中; 比较所述测量水平或水平组合; 并将所述水平或水平组合与所述患者内的银屑病表现相关联。一种药物组合物，包含大黄，升地黄和金银花的草药组合用于治疗患者中的牛皮癣。用于诊断和/或预测患者牛皮癣的试剂盒。

10. 发明申请

WO2018005308A1 PROGNOSTIC AND DIAGNOSTIC METHODS AND HERBAL THERAPIES FOR TREATING DERMATOSES, AUTOIMMUNE DISEASES AND INFLAMMATORY AILMENTS 审中-公开
标题翻译：用于治疗皮肤病，自身免疫疾病和炎性疾病的预后和诊断方法和草药治疗
公开(公告)号：WO2018005308A1
公开(公告)日：2018-01-04
申请号：PCT/US2017/039177
申请日：2017-06-26
申请人： SIRBAL LTD. , SHRAIBOM, Nadav , SINGH, Anu, T. , JAGGI, Manu , STEINBERG, Eran , VERMA, Ritu , MADAAN, Alka
发明人： SHRAIBOM, Nadav , SINGH, Anu, T. , JAGGI, Manu , STEINBERG, Eran , VERMA, Ritu , MADAAN, Alka
IPC分类号： G01N33/68 , A61K36/804 , A61K36/815 , A61K31/00 , A61K36/185 , A61K36/33 , A61K36/355 , A61K36/41 , A61K36/47 , A61K36/505 , A61K36/708 , A61K36/73
CPC分类号： G01N33/6893 , A61K31/352 , A61K38/00 , G01N33/6881 , G01N2333/525 , G01N2333/54 , G01N2800/202 , G01N2800/205
摘要： A medical kit for psoriasis, eczema or other inflammatory and/or autoimmune skin ailment, or for melanoma, BCC or other cancers, or leukemia, includes a swab or other tool for collecting skin samples, a multiplex cytokine assay for measuring levels of several cytokines, including IL-17, IL-23 and TNF-alpha, an indicator of a diagnostic test result, and a shampoo, lotion, cream ointment or nanogel or other topical medicinal formulation that includes a dosage composition including 20-160 mg/kg doses of an herbal combination of Sheng Di Huang, Da Huang and Jin Yin with an average particulate size that is less than 450 nm.
摘要翻译：用于牛皮癣，湿疹或其他炎性和/或自身免疫性皮肤疾病或用于黑素瘤，BCC或其他癌症或白血病的医学试剂盒包括用于采集皮肤样品的拭子或其他工具，多重用于测量包括IL-17，IL-23和TNF-α（一种诊断测试结果的指示剂）和洗发剂，洗剂，霜膏或纳米凝胶或其他局部药物制剂在内的几种细胞因子的水平的细胞因子测定法，包括盛地黄，大黄和金银的草药组合，剂量为20-160毫克/千克，平均粒径小于450纳米。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式